Sinovac Releases Positive Feedback from Swine Flu Vaccine Trial

Sinovac Biotech Ltd. (SVA) released an early report from the clinical trial of its A/H1N1 influenza vaccine, announcing that no severe adverse reactions were observed following the first inoculation. Participants experienced an 11.8% rate of adverse reactions. That is approximately equal to the average vaccine reaction and consisted mainly of pain at the injection site.

The vaccine was administered to 1,614 volunteers, including 101 elders, 706 adults, 404 juveniles and 403 children in the trial, which began on July 22, 2009. The trial participants, who were followed for a three-day observation period, exhibited only transient and mild reactions.

The clinical trial of the vaccine was organized by China's Center for Disease Control, and undertaken by Beijing CDC. The Ministry of Health and State Food and Drug Administration are also watching the trial.

The Ministry of Health has made an initial order of 4 million doses of Sinovac’s Panflu, which is expected to be delivered by the end of September.

Sinovac also launched its seasonal flu vaccine at the end of July 2009.

Disclosure: none.